LATEST DEVELOPMENTS

In January 2020, Irish-firm ERS Genomics licenses CRISPR gene editing technology to Japan’s Daiichi Sankyo to support internal research and development

In June 2020, US’ Vertex and CRISPR Therapeutics’ investigational CRISPR/Cas9 gene-editing therapy showed promise in more patients with sickle-cell disease

In June 2021, US’ Beam Therapeutics, Apellis inked a deal deal to apply base editing to discover novel therapies for complement-driven diseases

In June 2021, Swiss-American firm CRISPR Therapeutics has partnered with Capsida Biotherapeutics to discover and develop new gene-editing therapies for Friedreich’s ataxia

(FA) and familial amyotrophic lateral sclerosis (ALS)

In June 2021, US’ Gene editing startup Verve Therapeutics to raise $267 million in Initial Public Offering (IPO)

In July 2021, US’ Prime Medicine launches with $315 million financing to deliver on the promise of prime editing

In July 2021, US based Caribou Biosciences raised $304 million in one of gene editing’s most lucrative IPOs